KORU Medical Systems (NASDAQ:KRMD) Given New $3.50 Price Target at Piper Sandler

KORU Medical Systems (NASDAQ:KRMD) had its target price hoisted by Piper Sandler from $3.00 to $3.50 in a research note released on Thursday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Separately, B. Riley started coverage on shares of KORU Medical Systems in a report on Thursday, July 25th. They issued a “buy” rating and a $4.00 price target on the stock.

KORU Medical Systems Stock Up 2.9 %

KRMD stock opened at $3.17 on Thursday. KORU Medical Systems has a 1-year low of $1.98 and a 1-year high of $3.40. The stock has a market cap of $145.31 million, a price-to-earnings ratio of -12.68 and a beta of 0.41. The company has a current ratio of 2.99, a quick ratio of 3.27 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average is $2.67 and its 200 day moving average is $2.48.

Institutional Trading of KORU Medical Systems

Several large investors have recently added to or reduced their stakes in KRMD. Aaron Wealth Advisors LLC bought a new position in shares of KORU Medical Systems in the second quarter worth approximately $28,000. Allspring Global Investments Holdings LLC bought a new position in shares of KORU Medical Systems during the 2nd quarter valued at about $28,000. XTX Topco Ltd purchased a new position in KORU Medical Systems during the 3rd quarter valued at approximately $34,000. Legato Capital Management LLC bought a new stake in KORU Medical Systems in the second quarter worth $35,000. Finally, Virtu Financial LLC bought a new stake in shares of KORU Medical Systems in the 1st quarter worth about $63,000. 58.60% of the stock is currently owned by institutional investors.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.